Jeffrey D Milbrandt

This inventor holds 30 USPTO granted patents and 8 published patent applications, plus 1 CIPO patent and 4 EPO patents, primarily in Neurotrophic Factors. Top assignees: Washington University, Disarm Therapeutics, Inc., The United States of America, as Represented by the Secretary, Department of Health and Human Services. Active years: 1998-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Jeffrey D Milbrandt. Retrieved from https://idiyas.com/inventor/jeffrey-d-milbrandt

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 30 (Patent Applications = 8)

% Patents Active = 90.0

CIPO Patents = 1 (Patent Applications = 5)

EPO Patents = 4 (Patent Applications = 1)

Average Co-Inventor Count = 3.7

ph-index = 7

Forward Citations = 249(Granted Patents)

Location History:

Clayton, MO (US) (2012 - 2014)
St. Louis, MO (US) (1998 - 2023)
Saint Louis, MO (US) (2022 - 2024)

Company Filing History:

28 out of 1,381

Washington University

patents

2 out of 10

Disarm Therapeutics, Inc.

patents

2 out of 3,696

The United States of America, as Represented by the Secretary, Department of Health and Human Services

where one patent can have more than one assignee

Years Active: 1998-2026

Loading Chart...

Areas of Expertise:

SARM1

Neurolytic Agents

TCP Inhibitors

Genomic DNA Purification

Axonal Degeneration

AMPK Modulation

Persephin

Neurturin

Ninjurin

Growth Factors

Polynucleotides

Stem Cell Proliferation

30 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12576130 - DOMINANT NEGATIVE SARM1 MOLECULES COMPRISING A SUBSTITUTION AT POSITION 189, 190, 193, 194, 570 AND/OR 685 of SARM1 (2026-03-17),

2. 12390482 - Neurolytic agents and methods of using and identifying same (2025-08-19),

3. 12247246 - Identification of inhibitors of TcpC and TIR NADase activity (2025-03-11),

4. 11903935 - Inhibitors of SARM1 NADase activity and uses thereof (2024-02-20),

5. 11542495 - Preparative electrophoretic method for targeted purification of genomic DNA fragments (2023-01-03),

6. 11253503 - Inhibitors of SARM1 NADase activity and uses thereof (2022-02-22),

7. 9295688 - Methods and compositions for treating neuropathies (2016-03-29),

8. 8889126 - Methods and compositions for treating neuropathies (2014-11-18),

9. 8754060 - Methods and compositions for inhibition of axonal degeneration by modulation of the DLK/JNK pathway (2014-06-17),

10. 8133685 - AMPK modulation as a method of regulating stem cell and cancer stem cell proliferation, self-renewal and differentiation (2012-03-13),

11. 7776326 - Methods and compositions for treating neuropathies (2010-08-17),

12. 7649082 - Persephin specific antibodies (2010-01-19),

13. 7015316 - Polynucleotides encoding human persephin and related growth factors (2006-03-21),

14. 7015311 - Neurturin antibody (2006-03-21),

15. 6866851 - GFRα1-RET specific agonists and methods therefor (2005-03-15),

As an AI assistant specializing in innovations, inventions, inventors, patent attorneys, assignees, and patents, I can provide you with the requested article about inventor Jeffrey D Milbrandt. Here is the structure you asked for:

Title: Jeffrey D Milbrandt: A Visionary Inventor Shaping the Future

Introduction:

Jeffrey D Milbrandt, hailing from St. Louis, MO (US), is a distinguished inventor whose passion for innovation and relentless pursuit of excellence have solidified his reputation as a visionary in the world of technology and patents. With an impressive 26 patents to his name, Milbrandt's contributions have significantly shaped the landscape of modern inventions.

Latest Patents:

Two of Milbrandt's latest patents showcase his ingenuity:

1. Preparative electrophoretic method for targeted purification of genomic DNA fragments: This method involves entrapping particles containing high-molecular-weight (HMW) DNA in a gel matrix, exposing them to a lysis reagent, and subjecting the gel matrix to an electrophoretic field to purify the HMW DNA.

2. Inhibitors of SARM1 NADase activity and uses thereof: This patent focuses on compounds that inhibit SARM1 NADase activity, offering potential treatments for neurodegenerative or neurological diseases.

Career Highlights:

Milbrandt has made significant contributions at esteemed institutions. He has worked at Washington University and the National Institutes of Health, where his innovative spirit and commitment to excellence have driven groundbreaking research and advancements in technology.

Collaborations:

Throughout his career, Milbrandt has collaborated with accomplished professionals like Eugene M Johnson and Paul T Kotzbauer. These collaborations have led to the development of cutting-edge solutions and advancements in the field of inventions.

Conclusion:

In conclusion, Jeffrey D Milbrandt's dedication to innovation, coupled with his remarkable portfolio of patents, positions him as a leading figure in the realm of inventions and technology. His visionary approach and collaborative efforts continue to shape the future of patents and pave the way for transformative innovations.

Profile summary based on public USPTO records.